Pibrentasvir

From WikiMD's WELLNESSPEDIA

An antiviral medication used in the treatment of hepatitis C

Pibrentasvir

Pibrentasvir






























Pibrentasvir is an antiviral drug used in combination with other medications for the treatment of hepatitis C virus (HCV) infection. It is a component of the fixed-dose combination drug Glecaprevir/pibrentasvir, marketed under the brand name Mavyret.

Mechanism of Action[edit]

Pibrentasvir is a NS5A inhibitor, which means it targets the nonstructural protein 5A (NS5A) of the hepatitis C virus. NS5A is essential for viral replication and assembly, and by inhibiting this protein, pibrentasvir disrupts the life cycle of the virus, thereby reducing viral load in the patient's body.

Pharmacokinetics[edit]

Pibrentasvir is administered orally and is highly bioavailable. It is extensively metabolized in the liver and excreted primarily in the feces. The drug has a long half-life, allowing for once-daily dosing when used in combination with other antiviral agents.

Clinical Use[edit]

Pibrentasvir is used in combination with glecaprevir, a NS3/4A protease inhibitor, to treat adults with chronic hepatitis C virus infection. This combination is effective against all major genotypes of HCV, making it a pan-genotypic treatment option. The typical treatment duration is 8 to 12 weeks, depending on the patient's prior treatment history and the presence of cirrhosis.

Side Effects[edit]

Common side effects of pibrentasvir, when used in combination with glecaprevir, include headache, fatigue, and nausea. Serious side effects are rare but may include liver enzyme elevations and hypersensitivity reactions.

Contraindications[edit]

Pibrentasvir is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in those with known hypersensitivity to the drug or any of its components. Caution is advised when used in patients with moderate hepatic impairment (Child-Pugh B).

Related pages[edit]

  • Pibrentasvir
    Pibrentasvir

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Pibrentasvir&oldid=6334049"